Cerus Corporation

CERS • Medical - Devices

$2.59

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$511.19M

Growth

1.0%

Cash Flow

2/5

Trend

Volatile

Evidence

Positive revenue growth · 9.1%Positive free cash flow · 0.04Healthy liquidity · 1.73Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.59

Change0.00%

Shares Out197.37M

Market Cap$511.19M

Enterprise Value$496.90M

52W Range1.15 - 3.47

Beta1.77

P/E-75.36

P/S2.24

P/B7.23

P/FCF-545.56

EV/Sales2.18

Price$2.59

Change0.00%

Shares Out197.37M

Market Cap$511.19M

Enterprise Value$496.90M

52W Range1.15 - 3.47

Beta1.77

P/E-75.36

P/S2.24

P/B7.23

P/FCF-545.56

EV/Sales2.18

EV/EBITDA-89.37

EV/FCF-530.31

Earnings Yield-1.33%

FCF Yield-0.18%

Dividend Yield0.00%

Gross Margin53.50%

Oper. Margin-17.63%

Profit Margin-7.58%

Debt/Eq1.51

Current Ratio1.73

Quick Ratio1.17

Revenue 5Y0.97%

Target$4.00

Target Upside54.44%

Target Median$4.00

Target Range4.00 - 4.00

Volume1.78M

Avg Volume2.92M

EPS Surprise0.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

57/100

Growth Potential

Revenue and expansion

55/100

Price Attractiveness

Cheap or expensive today

53/100

Why this score▼

Positive revenue growth · 9.1%Positive free cash flow · 0.04Healthy liquidity · 1.73Weak profitability

Analyst view

Analyst sentiment and price target

CERS

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Price Target

2026-07-31

Low

$4.00

Mean

$4.00

Median

$4.00

High

$4.00

Company Overview

IPO: 1/31/1997

Industry: Medical - Devices

P/B i: 7.23

Debt / Equity i: 1.51

Operating Margin: -17.63%

Net Margin: -7.58%

ROE i: -

ROIC: -

Financial Health

Score11 / 20

Debt / Equity: 1.51

Current Ratio: 1.73

Quick Ratio: 1.17

Status: Moderate

Insider Transactions

Recent executive and insider activity

⚠ 3 high-volume insider sells detected

Jayaraman Vivek K

Transaction: 07/16/2026

SELL

Change

-16,666

Price

$3.16

Filing

07/20/2026

Type

SELL

Jayaraman Vivek K

Transaction: 07/01/2026

BUY

Change

+369,686

Price

Not reported

Filing

07/02/2026

Type

BUY

Jayaraman Vivek K

Transaction: 07/01/2026

BUY

Change

+554,529

Price

Not reported

Filing

07/02/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Jayaraman Vivek K	SELL	-16,666	$3.16	07/16/2026	07/20/2026
Jayaraman Vivek K	BUY	+369,686	Not reported	07/01/2026	07/02/2026
Jayaraman Vivek K	BUY	+554,529	Not reported	07/01/2026	07/02/2026
Greenman William Mariner	SELL	-101,919	$2.94	06/30/2026	07/02/2026
Jensen Chrystal	SELL	-24,329	$2.94	06/30/2026	07/02/2026
Jayaraman Vivek K	SELL	-42,359	$2.94	06/30/2026	07/02/2026
Green Kevin Dennis	SELL	-33,676	$2.94	06/30/2026	07/02/2026
BJERKHOLT ERIC	SELL	-20,454	$2.60	06/09/2026	06/11/2026
Shan Hua	BUY	+60,000	Not reported	06/02/2026	06/02/2026
Gregory Dean A.	BUY	+60,000	Not reported	06/02/2026	06/02/2026
Witney Frank	BUY	+60,000	Not reported	06/02/2026	06/02/2026
NACHTSHEIM JAMI K	BUY	+60,000	Not reported	06/02/2026	06/02/2026
BJERKHOLT ERIC	BUY	+60,000	Not reported	06/02/2026	06/02/2026
Lucena Ann	BUY	+60,000	Not reported	06/02/2026	06/02/2026
Jayaraman Vivek K	SELL	-16,667	$3.00	05/29/2026	06/02/2026
Jayaraman Vivek K	SELL	-16,667	$3.00	05/01/2026	05/05/2026
Jensen Chrystal	BUY	+200,000	Not reported	04/01/2026	04/03/2026
Green Kevin Dennis	BUY	+200,000	Not reported	04/01/2026	04/03/2026
Benjamin Richard J	SELL	-101,740	$1.66	03/12/2026	03/16/2026
Green Kevin Dennis	SELL	-127,544	$1.66	03/12/2026	03/16/2026

About the Company

Cerus Corporation

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

Source - link

Peers

CVRX MASS NPCE QTRX RXST SENS SGHT SNWV TBRG TKNO

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Cerus: This Blood-Safety Underdog Should Be Earning More Respect

Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting growing confidence in commercial momentum.

Seeking Alpha

Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS

Assenagon Asset Management S.A. lessened its holdings in Cerus Corporation (NASDAQ: CERS) by 74.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 315,050 shares of the biotechnology company's stock after selling 936,043 shares during the quarter.

Defense World

Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript

Seeking Alpha

Cerus Q2 Earnings Call Highlights

Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.

MarketBeat

Cerus Corporation Announces Second Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made significant progress in expanding patient access to safer blood components around the globe,” said Vivek Jayaraman, Cerus' president and chief executive officer. “I'm particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for b.

Business Wire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-30	-0.03	-0.01	0.02
2026-03-02	-0.01	-0.01	0
2025-11-06	-0.02	-0.0001	0.0199
2025-08-05	-0.02	-0.03	-0.01
2025-05-01	-0.05	-0.04	0.01
2025-02-20	-0.01	-0.01	0
2024-10-30	-0.015	-0.02	-0.005
2024-08-01	-0.024	-0.03	-0.006
2024-05-02	-0.04667	-0.05	-0.00333
2024-03-05	-0.00632	-0.01	-0.00368
2023-11-02	-0.05	-0.03	0.02
2023-08-02	-0.05	-0.07	-0.02